Using Biomarkers to Optimize Antibiotic Strategies in Sepsis
Using Biomarkers to Optimize Antibiotic Strategies in Sepsis
The proposed work will provide critical insights into the potential impact of a
 biomarker-based algorithm on reducing unnecessary antibiotic use in different adult and
 pediatric/neonatal ICU's. This proposal will also assess the costs (or savings) of a
 biomarker-based intervention. Overall, the results of this work will be critical in informing
 future strategies to eliminate unnecessary antibiotic use and curb the continued rise in
 antimicrobial resistance.
The goal of this project is reduce unnecessary use of antibiotics in the ICU. The purpose of
 Phase I of the study is to identify the biomarker, or combination of biomarkers, that
 provides optimal test characteristics in identifying adults and children/neonates with
 presumed sepsis who have a very low likelihood of bacterial infection. Results of Phase I
 will result in development of a biomarker-based algorithm to inform need for antibiotic use
 in ICU patients. In Phase II, the impact of this biomarker-based algorithm on reducing
 antibiotic use in the ICU will be determined. Costs or savings associated with the algorithm
 will also be assessed.
Inclusion Criteria:

 1. SIRS Criteria

 SIRS is considered to be present when patients have more than one of the following
 clinical findings:

 -  body temperature >38°C or <36°C

 -  heart rate >90 min-1

 -  respiratory rate of >20 min-1 or a Paco2 of <32 mm Hg

 -  and a white blood cell count of >12,000 cells µL-1 or <4,000 µL-1

 2. new empiric antibiotic therapy is initiated, indicating the suspicion of infection.
 Accepted criteria for SIRS will be used for the Medical Intensive Care Unit and
 Surgical Intensive Care Unit populations, with appropriate age-specific vital signs
 definitions to help make the definitions relevant for the Pediatric Intensive Care
 Unit population.

 Exclusion Criteria:

 1. a code status of "do not resuscitate"

 2. absence of initiation or expansion of antibiotic therapy despite meeting criteria for
 sepsis

 3. presence of an immunocompromising condition.

 An immunocompromising condition will be defined as one of the following:

 -  human immunodeficiency virus (HIV) infection with a t-helper cell (CD4) count <200
 cell/mm3; 2) immunosuppressive therapy after organ transplantation

 -  neutropenia (<500 neutrophils/mm3)

 -  active chemotherapy within the 3 months preceding eligibility or

 -  diagnosis of cystic fibrosis.

 These criteria all represent conditions in which antibiotic use is much less likely to be
 decreased regardless of the results of a biomarker and are consistent with exclusion
 criteria used in past studies of the impact of biomarkers.